Cytotoxic T lymphocyte associated antigen 4 expression predicts poor prognosis in luminal B HER2-negative breast cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Oncology Letters

• Publication date

  2018-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/ol.2018.7991PMID 29552143PMCID PMC5840684
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Ki-67 Expression by Immunohistochemistry and Quantitative Real-Time Polymerase Chain Reaction as Predictor of Clinical Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

  2017cited by this paper
• Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013

  2017cited by this paper
• Cancer statistics in China, 2015

  2016cited by this paper
• Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis

  2016cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• Epidemiological and Clinicopathological Trends of Breast Cancer in Chinese Patients During 1993 to 2013

  2015cited by this paper
• Epidemiological and Clinicopathological Trends of Breast Cancer in Chinese Patients During 1993 to 2013

  2015cited by this paper
• Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis

  2015cited by this paper
• Breast cancer statistics, 2013

  2014cited by this paper
• TGF-β1 precursor and CD8 are potential prognostic and predictive markers in operated breast cancer

  2014cited by this paper
• Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer

  2014cited by this paper
• Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013

  2013cited by this paper
• CTLA-4 blockade in tumor models: an overview of preclinical and translational research.

  2013cited by this paper
• Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer

  2012cited by this paper
• Comprehensive molecular portraits of human breast tumors

  2012cited by this paper
• [Estimates and prediction on incidence, mortality and prevalence of breast cancer in China, 2008].

  2012cited by this paper
• T-bet+ Treg Cells Undergo Abortive Th1 Cell Differentiation due to Impaired Expression of IL-12 Receptor β2

  2012cited by this paper
• Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade

  2012cited by this paper
• Luminal-B breast cancer and novel therapeutic targets

  2011cited by this paper
• Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

  2010cited by this paper
• New insights of CTLA-4 into its biological function in breast cancer.

  2010cited by this paper
• CTLA-4 is expressed by human monocyte-derived dendritic cells and regulates their functions.

  2010cited by this paper
• Supplementary Tables

  2009cited by this paper
• Structural basis for co-stimulation by the human CTLA-4/B7-2 complex

  2001cited by this paper
• Cancer statistics

  1989cited by this paper

• Machine learning-based radiomics analysis on contrast-enhanced MRI for prediction of cytotoxic T-lymphocyte associated protein 4 expression in patients with breast cancer.

  2025cites this paper
• Immunohistochemical Expression of PD-L1 and CTLA-4 in Triple Negative Breast Cancer and Their Prognostic Associations

  2025cites this paper
• Targeting LAG-3: Relatlimab, Fianlimab, and ieramilimab reshape the landscape of cancer combination immunotherapy.

  2025cites this paper
• MiRNA affects the advancement of breast cancer by modulating the immune system's response.

  2025cites this paper
• High CTLA-4 gene expression is an independent good prognosis factor in breast cancer patients, especially in the HER2-enriched subtype

  2024cites this paper
• CD47 plays dual role in colorectal carcinoma, independently on CD 68: an immunohistochemical study

  2024cites this paper
• A molecular and immunohistochemical study of 37 cases of ovarian Sertoli–Leydig cell tumor

  2024cites this paper
• Advances in immunotherapy for breast cancer and feline mammary carcinoma: From molecular basis to novel therapeutic targets.

  2024cites this paper
• An extensive immunohistochemical analysis of 290 ovarian adult granulosa cell tumors with 29 markers

  2024cites this paper
• The Role of Beclin 1 and HER2 in Colorectal Carcinoma; An Immunohistochemical Study

  2024cites this paper
• Traditional Chinese medicine enhances the effectiveness of immune checkpoint inhibitors in tumor treatment: A mechanism discussion.

  2024cites this paper
• PYCR1, BANF1, and STARD8 Expression in Gastric Carcinoma: A Clinicopathologic, Prognostic, and Immunohistochemical Study

  2023cites this paper
• Immunohistochemical Expression of Immune Checkpoints; CTLA-4, LAG3, and TIM-3 in Cancer Cells and Tumor-infiltrating Lymphocytes (TILs) in Colorectal Carcinoma

  2023cites this paper
• Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) as an undetermined tool in tumor cells

  2023cites this paper
• Natural Products and their Derivatives as Immune Check Point Inhibitors: Targeting Cytokine/Chemokine Signalling in Cancer.

  2022cites this paper
• Immune-Based Therapy in Triple-Negative Breast Cancer: From Molecular Biology to Clinical Practice

  2022cites this paper
• CTLA-4 Expression and Its Clinical Significance in Breast Cancer

  2021cites this paper
• The role and relationship between programmed death ligand 1 and cytotoxic T lymphocyte-associated antigen-4 immunohistochemical expression in colorectal carcinoma patients: an impact on outcome

  2021cites this paper
• The Clinical Value of VDR and CTLA 4 in Evaluating the Prognosis of Invasive Duct Carcinoma of Egyptian Patients and their Benefit as a Target Therapy

  2021cites this paper
• The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy

  2021cites this paper
• From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past

  2021cites this paper
• News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors.

  2020cites this paper
• Clinical Relevance of the serum CTLA-4 in Cats with Mammary Carcinoma

  2020influential citation
• Immune checkpoints in the tumor microenvironment.

  2020cites this paper
• Identification of a prognostic long non-coding RNA signature in breast cancer

  2020cites this paper
• NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells

  2020cites this paper
• Clinical value of CTLA4 combined with clinicopathological factors in evaluating the prognosis of breast cancer.

  2020influential citation
• Immune microenvironment in different molecular subtypes of ductal breast carcinoma

  2020cites this paper
• Chimeric antigen receptor T cells in solid tumors: a war against the tumor microenvironment

  2019influential citation